Trial Profile
A Phase 3b Multicenter, Open-Label Single Arm Study of Roxadustat: Either as Conversion From a Continuous Erythropoietin Receptor Activator (CERA), or as Initial Anemia Treatment in Hemodialysis (HD) Patients - DENALI Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Roxadustat (Primary)
- Indications Anaemia
- Focus Registrational; Therapeutic Use
- Acronyms DENALI Study
- Sponsors FibroGen
- 31 Jan 2022 Status changed from active, no longer recruiting to completed.
- 20 Apr 2021 Planned End Date changed from 1 Jul 2021 to 28 Aug 2021.
- 20 Apr 2021 Planned primary completion date changed from 1 Jan 2021 to 31 Jul 2021.